Hutchmed scores U.S. success with cancer drug, but profits still dip
The drug developer has reported sharply reduced profits, coming off an exceptionally high base last year, but sales of its key cancer medicine are accelerating in the United States Key…
FAST NEWS: Hutchmed Sells Cancer Drug’s Overseas Rights for up to $1.13 Billion
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced on Wednesday that it has exclusively licensed Japan’s Takeda Pharmaceutical (TAK.US; 4502.T) to develop, manufacture and sell its metastatic colorectal cancer drug…
RELATED ARTICLES
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG -
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
